Petersenn, S.
Salgado, L. R.
Schopohl, J.
Portocarrero-Ortiz, L.
Arnaldi, G.
Lacroix, A.
Scaroni, C.
Ravichandran, S.
Kandra, A.
Biller, B. M. K.
Funding for this research was provided by:
Novartis Pharma AG
Article History
Received: 9 August 2016
Accepted: 1 May 2017
First Online: 9 June 2017
Compliance with ethical standards
:
: S.P. has served as consultant for Novartis and Ipsen; L.R.S. has served as a consultant for Novartis; J.S. has served as a consultant for Novartis, Ipsen, and Pfizer and has received grants for clinical studies from Novartis, Ipsen, Pfizer, Chiasma, Teva, Sandoz, and Lilly; L.P.O., G.A. and C.S. have no conflicts of interest to report. A.L. has received research support and served as a consultant for Novartis, EMD Serono and Strongbridge Biopharma. S.R. and A.K. are employees of Novartis. B.M.K.B. has served as principal investigator on studies with research grants from Novartis and Cortendo to the Massachusetts General Hospital and as a consultant to Novartis, Cortendo, HRA Pharma, and Ipsen.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.